EUVIMEDEUVIMED entdecken
Crossref

Advanced therapy is delayed in pediatric South Asian inflammatory bowel disease patients in the United States

Megha Tandon, Jennifer Bachand, Nurgul Yegembayeva, Lauren V Collen iD, Sushrut Jangi iD

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.70233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Megha Tandon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Time-to-Treatment. Die Arbeit nennt 15 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

South Asian pediatric inflammatory bowel disease (SA pIBD) is a novel at‐risk demographic group for pediatric IBD. However, the disease characteristics and treatment strategies for SA pIBD in the United States remain poorly described.

Methods

In this retrospective cohort study of 147 patients, SA patients with pIBD ( n = 55) were matched (~1:2) to non‐South Asian (NSA, n = 92) patients with pIBD by age, sex, and disease subtype. Study outcomes included demographics, disease extent and severity, treatments utilized, and patient perspectives on pIBD and its treatment.

Results

Among 55 SA and matched 92 NSA pIBD patients, mean age of presentation was 12 years old, with male predominance (65%), and majority with a Crohn's diagnosis (65%). Very early‐onset IBD (VEOIBD) was reported in 5.5% of SA pIBD. SA pIBD patients more frequently presented with weight loss, left‐sided disease, upper gastrointestinal manifestations, and elevated erythrocyte sedimentation rate. SA pIBD patients were less likely to use biologic therapies as their initial treatment (9.1% vs. 30.4%, p < 0.005), with a lower cumulative rate of biologic use. Instead, SA pIBD were more likely to use mesalamine or other treatments as their initial therapy.

Conclusions

SA pIBD had unique phenotypic characteristics compared to NSA pIBD. SA pIBD patients were less likely to initiate biologic therapies as their initial treatment and had a longer time‐to‐initiation of biologic therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesTime-to-TreatmentHumansMaleChildFemaleRetrospective StudiesUnited StatesAdolescentSeverity of Illness IndexChild, PreschoolCrohn DiseaseAge of OnsetColitis, Ulcerative

Stichwörter der Autor:innen

Crohn's diseaseulcerative colitisvery early onset inflammatory bowel disease

Autor:innen und Institutionen

  • Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Internal Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Lauren V Collen, Sushrut Jangi

Förderung

  • None

Zitieren

APA

Tandon, M., Bachand, J., Yegembayeva, N., Collen, L. V., & Jangi, S. (2025). Advanced therapy is delayed in pediatric South Asian inflammatory bowel disease patients in the United States. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70233

Vancouver

Tandon M, Bachand J, Yegembayeva N, Collen LV, Jangi S. Advanced therapy is delayed in pediatric South Asian inflammatory bowel disease patients in the United States. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70233

BibTeX
@article{Tandon2025,
  author = {Tandon, Megha and Bachand, Jennifer and Yegembayeva, Nurgul and Collen, Lauren V and Jangi, Sushrut},
  title = {Advanced therapy is delayed in pediatric South Asian inflammatory bowel disease patients in the United States},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.70233}
}
Kostenlos starten →